Cargando…
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
IMPORTANCE: There is currently no standard treatment strategy for patients with advanced non–small cell lung cancer (NSCLC) without driver gene variation after failure of 2 or more lines of chemotherapy. OBJECTIVE: To assess the efficacy and safety of apatinib combined with oral vinorelbine. DESIGN,...
Autores principales: | Zhang, Xiangyu, Xiong, Yi, Xia, Qing, Wu, Fang, Liu, Lingli, Zhou, Yuling, Zeng, Liang, Zhou, Chunhua, Xia, Chen, Jiang, Wenjuan, Liao, Dehua, Xiao, Lili, Liu, Li, Yang, Haiyan, Guan, Rui, Li, Kunyan, Wang, Jing, Lei, Guang, Zhang, Yongchang, Yang, Nong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082721/ https://www.ncbi.nlm.nih.gov/pubmed/32191330 http://dx.doi.org/10.1001/jamanetworkopen.2020.1226 |
Ejemplares similares
-
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022) -
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
por: Jiang, Wenjuan, et al.
Publicado: (2022) -
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
por: Zhang, Yongchang, et al.
Publicado: (2022) -
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023) -
The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer
por: Chen, Gong, et al.
Publicado: (2017)